Recursion Pharmaceuticals, Inc. Director Blake Borgeson is set to sell 11,447 Class A shares of the company on 07/09/2024, as per the latest SEC filing. These shares, originally acquired on 09/01/2016 as founder's shares in compensation for Borgeson's role, are valued at an aggregate market value of $83,734.73. This planned sale follows a series of transactions over the past three months, where a total of 77,289 shares were sold for gross proceeds of approximately $692,134.77. The upcoming sale represents a continuation of Borgeson's regular divestment of shares in the company.

Recursion Pharmaceuticals, Inc. Director Blake Borgeson is set to sell 11,447 Class A shares of the company on 07/09/2024, as per the latest SEC filing. These shares, originally acquired on 09/01/2016 as founder's shares in compensation for Borgeson's role, are valued at an aggregate market value of $83,734.73. This planned sale follows a series of transactions over the past three months, where a total of 77,289 shares were sold for gross proceeds of approximately $692,134.77. The upcoming sale represents a continuation of Borgeson's regular divestment of shares in the company.